| 0 (0%) | 10-15 12:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.93 | 1-year : | 12.46 |
| Resists | First : | 10.22 | Second : | 10.67 |
| Pivot price | 10.08  |
|||
| Supports | First : | 9.48 | Second : | 7.89 |
| MAs | MA(5) : | 9.89 |
MA(20) : | 10.02 |
| MA(100) : | 8.78 |
MA(250) : | 8.38 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 20.5 |
D(3) : | 30.3 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 10.67 | Low : | 6.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMRX ] has closed above bottom band by 22.5%. Bollinger Bands are 40.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.81 - 9.88 | 9.88 - 9.94 |
| Low: | 9.45 - 9.55 | 9.55 - 9.62 |
| Close: | 9.59 - 9.72 | 9.72 - 9.81 |
Wed, 15 Oct 2025
How analysts rate AMRX stock today - 2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
Tue, 14 Oct 2025
Assessing Amneal Pharmaceuticals (AMRX) Valuation After BLA Submission and Eased Regulatory Risks - Sahm
Tue, 14 Oct 2025
3 of Wall Street’s Favorite Stocks We Find Risky - TradingView
Mon, 13 Oct 2025
Assessing Amneal Pharmaceuticals (AMRX) Valuation After BLA Submission and Eased Regulatory Risks - simplywall.st
Sat, 11 Oct 2025
How Amneal’s (AMRX) Biosimilar XOLAIR Application Could Shape Its Specialty Pharma Ambitions - simplywall.st
Sat, 11 Oct 2025
How Amneal’s (AMRX) Biosimilar XOLAIR Application Could Shape Its Specialty Pharma Ambitions - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 314 (M) |
| Shares Float | 179 (M) |
| Held by Insiders | 46.4 (%) |
| Held by Institutions | 46.3 (%) |
| Shares Short | 5,690 (K) |
| Shares Short P.Month | 5,110 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.37 |
| Profit Margin | 0.1 % |
| Operating Margin | 15.4 % |
| Return on Assets (ttm) | 6.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 3.2 % |
| Gross Profit (p.s.) | 3.4 |
| Sales Per Share | 9.07 |
| EBITDA (p.s.) | 1.99 |
| Qtrly Earnings Growth | 261 % |
| Operating Cash Flow | 351 (M) |
| Levered Free Cash Flow | 334 (M) |
| PE Ratio | 972.96 |
| PEG Ratio | 0 |
| Price to Book value | -27.03 |
| Price to Sales | 1.07 |
| Price to Cash Flow | 8.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|